U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07251868) titled 'Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study' on Sept. 24.
Brief Summary: The goal of this real-world study (RWS) is to evaluate the effectiveness of Trop-2 ADC (sacituzumab govitecan) in treating breast cancer patients with brain metastases, and to understand the safety profile of this drug in real clinical practice across multiple centers. The main questions it aims to answer are:
Does Trop-2 ADC (sacituzumab govitecan) improve intracranial outcomes in breast cancer patients with brain metastases (e.g., intracranial objective response rate, intracranial progression-free survival)? W...